Form 4: RAPT CEO Sells All Shares in GSK Merger

RAPT Therapeutics CEO Brian Russell Wong disposed of all common stock and stock options following the company's acquisition by GlaxoSmithKline for $58.00 per share.

Summary

• RAPT Therapeutics, Inc. was acquired by GlaxoSmithKline LLC, with Redrose Acquisition Co. completing a tender offer for $58.00 per share in cash.
• The merger became effective on March 3, 2026, making RAPT an indirect wholly-owned subsidiary of GlaxoSmithKline.
• Brian Russell Wong, President and CEO, disposed of 64,102 shares of common stock at the $58.00 offer price.
• All outstanding employee stock options, whether vested or unvested, were accelerated and became fully vested and exercisable immediately prior to the Effective Time.
• Stock options with an exercise price less than the $58.00 Offer Price were cancelled and converted into cash payments.
• Unvested options granted after March 1, 2025, were converted into cash-based awards of GlaxoSmithKline, vesting 50% on the closing date and 50% nine months later, with accelerated vesting on involuntary termination.
• A 1-for-8 reverse stock split was effected on June 16, 2025, which adjusted the reported share and option numbers.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive event for RAPT shareholders, including the reporting person, as it represents a successful acquisition at a fixed cash price, providing liquidity and a premium for their holdings. The acceleration and cash-out of options also benefit the insider.

Positives

• The reporting person received cash for all common stock at the tender offer price of $58.00 per share.
• All outstanding stock options (vested or unvested) were accelerated and became fully vested and exercisable prior to the merger.
• Options with an exercise price below the offer price were cashed out, providing a direct financial benefit.
• Certain unvested options were converted into cash-based awards from the acquiring company, providing continued incentive and potential future payout.

Negatives

• The reporting person no longer holds any direct beneficial ownership in RAPT Therapeutics, Inc. common stock or derivative securities.
• RAPT Therapeutics, Inc. ceased to be an independent publicly traded entity.

Future Outlook

The filing indicates that RAPT Therapeutics, Inc. has become an indirect wholly-owned subsidiary of GlaxoSmithKline LLC, implying its future operations and strategic direction will be integrated within GSK's broader corporate structure. Certain unvested options were converted into cash-based awards from Parent, with vesting scheduled 50% on the closing date and 50% nine months thereafter, suggesting a retention mechanism for key personnel post-acquisition.

Industry Context

StockSavvy.ai notes that this acquisition by GlaxoSmithKline of RAPT Therapeutics reflects a continuing trend of larger pharmaceutical companies acquiring smaller biotech firms to bolster their pipelines and intellectual property. Such mergers often aim to integrate promising drug candidates or technological platforms into the acquirer's portfolio, reducing competition and expanding market reach. The tender offer price of $58.00 per share represents a valuation agreed upon by both parties, indicative of the perceived value of RAPT's assets within the biopharmaceutical sector.

Comparison to Industry Standards

• StockSavvy.ai observes that the tender offer price of $58.00 per share for RAPT Therapeutics, Inc. common stock is a specific valuation for this transaction. Without detailed financial performance metrics for RAPT or comparable acquisition multiples for similar biotech firms in the same therapeutic areas (e.g., immunology, oncology, where RAPT had programs), a direct comparison to industry standards or specific comparable companies like Pfizer's acquisition of Seagen or Merck's acquisition of Acceleron Pharma is not feasible based solely on this Form 4. However, the cash consideration and option treatment are standard mechanisms in such M&A transactions.

Stakeholder Impact

• Shareholders: Received $58.00 per share in cash, providing a definitive return on investment.
• Employees: Stock options were either cashed out or converted into cash-based awards from the acquiring company, providing financial benefits and retention incentives.
• Company (RAPT): Ceased to be an independent public entity, becoming part of GlaxoSmithKline.

Next Steps

• Integration of RAPT Therapeutics, Inc. into GlaxoSmithKline LLC's operations.
• Continued vesting and payment of Converted Options for certain employees, including potentially the reporting person, over the next nine months.

Key Dates

Keywords

RAPT Therapeutics, GlaxoSmithKline, GSK, Merger, Acquisition, Tender Offer, Form 4, Insider Trading, Stock Options, Brian Russell Wong, Common Stock, Corporate Action